Last updated on December 2010

A randomized , double-blind, placebo-controlled , multicenter, two-part, dose ranging and confirmatory study with an operationally seamless design, evaluating efficacy and safety of IL-6Ra mAb on top of methotrexate in patients with active rheumatoid arthritis who are inadequate responders of MTX therapy.


Brief description of study

A randomized , double-blind, placebo-controlled , multicenter, two-part, dose ranging and confirmatory study with an operationally seamless design, evaluating efficacy and safety of IL-6Ra mAb on top of methotrexate in patients with active rheumatoid arthritis who are inadequate responders of MTX therapy.

Detailed Study Description

Do you have Rheumatoid arthritis? You may qualify to participate in a clinical research study.

IL-6Ra mAb is a randomized placebo controlled trial of an injectable IL-6Rmab for patient with active rheumatoid arthritis on methotrexate with active joint disease. There is 22 weeks of randomization followed by 58 weeks of open label extension.

Clinical Study Identifier: TX135178

.

Contact Investigators or Research Sites near you

Start Over

Please choose location

View all locations

The Center for Rheumatology and ...

The Center for Rheumatology and Bone Research
Wheaton, MD USA
  Connect »